<DOC>
	<DOCNO>NCT00255034</DOCNO>
	<brief_summary>This Australian , open-label , multicenter , randomize , double-blind clinical trial design assess efficacy combination therapy pegylated interferon alfa-2b ribavirin 48 week versus 24 week treatment chronic hepatitis C ( treatment-naïve genotype 3 subject high viral load METAVIR score least F1A2 ) . The primary endpoint sustain virological response define undetectable HCV RNA serum 24 week completion therapy .</brief_summary>
	<brief_title>Effects 48 Weeks Versus 24 Weeks Therapy With Peg-Intron/Ribavirin Patients With Chronic Hepatitis C , Genotype 3 ( Study P04143 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Comply current Australian Schedule Pharmaceutical Benefits S100 eligibility criterion . Chronic hepatitis C genotype 3 infection viral load least 2 million copy per mL . Able give write informed consent . Understand able adhere dose visit schedule . Compensated liver disease follow minimum hematologic biochemical criterion : Hemoglobin ≥120 g/L ( female ) , ≥130 g/L ( male ) Platelets ≥100 x 10^9/L Neutrophil count ≥1.5 x 10^9/L Creatinine clearance &gt; 50 mL/minute Thyroid stimulate hormone ( TSH ) within normal limit Serum hepatitis B surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) negative . Negative pregnancy test . Suspected hypersensitivity interferon , pegylated interferon alfa2b , ribavirin . Participation investigational drug program within 30 day screen visit protocol . Any cause liver disease base patient history biopsy chronic hepatitis C , include limited : hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's disease , autoimmune hepatitis , alcoholic liver disease , drugrelated liver disease . Hepatocellular carcinoma . Decompensated cirrhosis ( ascites , history encephalopathy bleeding varix , serum albumin &lt; 35 g/L , prothrombin time ( PT ) prolong great 3 sec ) . Significant cardiovascular dysfunction within past 6 month ( e.g. , angina , congestive heart failure , myocardial infarction , severe hypertension , significant arrhythmia ) participant ECG show clinically significant abnormality . Immunologicallymediated disease , ( e.g . inflammatory bowel disease ) , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ) . Hemophilia hemoglobinopathy , include limit thalassemia major . Severe psychiatric condition , include major depression , history major psychosis , current suicidal ideation , and/or suicidal attempt . Ongoing substance abuse , e.g . alcohol , I.V . drug inhalant opinion investigator would jeopardize patient 's ability comply study requirement . Clinically significant ophthalmological disorder . Treatment recent treatment immunosuppressive agent ( exclude shortterm corticosteroid withdrawal ) immunosuppressed transplant recipient . Poorly control thyroid disease . Any condition opinion investigator would make patient unsuitable enrolment , could interfere patient participate complete clinical trial program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>pegylated interferon alfa-2b</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Australia</keyword>
</DOC>